Wall Street analysts expect that Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) will report earnings of ($0.78) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Eiger Biopharmaceuticals’ earnings. The lowest EPS estimate is ($0.84) and the highest is ($0.72). Eiger Biopharmaceuticals reported earnings of ($0.82) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 4.9%. The business is scheduled to announce its next quarterly earnings report on Friday, August 9th.

On average, analysts expect that Eiger Biopharmaceuticals will report full-year earnings of ($2.55) per share for the current financial year, with EPS estimates ranging from ($3.30) to ($0.81). For the next financial year, analysts expect that the firm will post earnings of ($2.92) per share, with EPS estimates ranging from ($3.45) to ($2.37). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that follow Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.90) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $0.05.

EIGR has been the topic of a number of research analyst reports. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Zacks Investment Research upgraded shares of Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 target price on the stock in a research note on Monday. Citigroup restated a “hold” rating on shares of AbbVie in a research note on Wednesday, June 26th. LADENBURG THALM/SH SH restated a “buy” rating and issued a $28.00 target price on shares of Eiger Biopharmaceuticals in a research note on Tuesday, June 18th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $74.00 price target on shares of Tempur Sealy International in a research report on Tuesday, June 18th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Eiger Biopharmaceuticals presently has an average rating of “Buy” and a consensus price target of $28.34.

In other Eiger Biopharmaceuticals news, Director Thomas John Dietz purchased 5,000 shares of the stock in a transaction dated Monday, April 22nd. The stock was purchased at an average price of $11.05 per share, with a total value of $55,250.00. Following the transaction, the director now owns 15,000 shares of the company’s stock, valued at $165,750. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders bought a total of 7,250 shares of company stock valued at $80,130 in the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at approximately $114,000. Wedbush Securities Inc. purchased a new stake in Eiger Biopharmaceuticals during the first quarter valued at approximately $179,000. Millennium Management LLC purchased a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at approximately $255,000. Bank of America Corp DE lifted its position in Eiger Biopharmaceuticals by 49.6% during the fourth quarter. Bank of America Corp DE now owns 25,884 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 8,581 shares during the last quarter. Finally, Sanders Morris Harris LLC purchased a new stake in Eiger Biopharmaceuticals during the second quarter valued at approximately $344,000. 80.03% of the stock is owned by institutional investors.

EIGR stock traded up $0.04 during mid-day trading on Thursday, reaching $11.31. The company had a trading volume of 3,153 shares, compared to its average volume of 182,397. The company has a debt-to-equity ratio of 0.62, a current ratio of 8.16 and a quick ratio of 8.16. The stock has a market cap of $217.06 million, a P/E ratio of -2.93 and a beta of 1.07. The business has a 50 day moving average of $10.71. Eiger Biopharmaceuticals has a 12 month low of $8.40 and a 12 month high of $15.33.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

See Also: Leveraged Buyout (LBO)

Get a free copy of the Zacks research report on Eiger Biopharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.